DIMERIX INVESTOR CALL & PRESENTATION
Development pipeline
Program Indication
Focal Segmental Glomerular Sclerosis
(FSGS)
DMX-200
Diabetic Kidney Disease
Late COVID pneumonia – REMAP-CAP
Preclinical Phase 1
Phase 2
Phase 3
Key milestones
Phase 2a demonstrated encouraging efficacy & safety¹; Phase 3 underway
with regulatory &/or ethics authorisation in multiple countries², recruitment
of 1st patients planned Q1 22, 1st interim data anticipated H1 233
Phase 2 demonstrated promising efficacy and safety, planning of next
study design underway
Early COVID respiratory - CLARITY 2.0
DMX-700
Chronic Obstructive Pulmonary Disease
(COPD)
DMX-XXX
Undisclosed (multiple)
Recruitment underway across Europe4, initial data anticipated Q1 223
Recruitment underway across India 5, ethics approval in Australia, interim
data from India anticipated Q1 223
Pre-clinical studies underway to support entry into clinical studies; data
anticipated Q2 22
Additional target opportunities identified using Receptor-HIT; preliminary
exploratory work underway
Dimerix
1 ASX releases: 12Jul17, 180ct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21
2 ASX releases: 21Oct21, 01Feb22 (Australia, Denmark); + Taiwan approved on 08Feb22
3 Subject to recruitment
4 ASX release: 23Apr21, 16Dec21
5 ASX release: 11Jan22
6 ASX release: 23Dec21
5View entire presentation